- Home
- CRSP vs LEGN Comparison
CRSP vs LEGN Comparison
Compare CRSP & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- LEGN
- Stock Information
- Founded
- CRSP 2013
- LEGN 2014
- Country
- CRSP Switzerland
- LEGN United States
- Employees
- CRSP N/A
- LEGN N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CRSP Health Care
- LEGN Health Care
- Exchange
- CRSP Nasdaq
- LEGN Nasdaq
- Market Cap
- CRSP 5.6B
- LEGN 5.9B
- IPO Year
- CRSP 2016
- LEGN 2020
- Fundamental
- Price
- CRSP $52.57
- LEGN $30.33
- Analyst Decision
- CRSP Buy
- LEGN Strong Buy
- Analyst Count
- CRSP 19
- LEGN 13
- Target Price
- CRSP $71.94
- LEGN $72.92
- AVG Volume (30 Days)
- CRSP 2.5M
- LEGN 1.3M
- Earning Date
- CRSP 11-10-2025
- LEGN 11-12-2025
- Dividend Yield
- CRSP N/A
- LEGN N/A
- EPS Growth
- CRSP N/A
- LEGN N/A
- EPS
- CRSP N/A
- LEGN N/A
- Revenue
- CRSP $38,337,000.00
- LEGN $909,045,000.00
- Revenue This Year
- CRSP N/A
- LEGN $68.68
- Revenue Next Year
- CRSP $391.94
- LEGN $48.49
- P/E Ratio
- CRSP N/A
- LEGN N/A
- Revenue Growth
- CRSP N/A
- LEGN 74.75
- 52 Week Low
- CRSP $30.04
- LEGN $27.34
- 52 Week High
- CRSP $78.48
- LEGN $45.30
- Technical
- Relative Strength Index (RSI)
- CRSP 34.88
- LEGN 33.91
- Support Level
- CRSP $52.42
- LEGN $29.92
- Resistance Level
- CRSP $58.48
- LEGN $33.50
- Average True Range (ATR)
- CRSP 3.56
- LEGN 1.33
- MACD
- CRSP -1.14
- LEGN -0.10
- Stochastic Oscillator
- CRSP 21.64
- LEGN 10.89
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.